Skip to main content
Clinical Fact Sheet

Wegovy Pill®

Oral tablet. GLP-1 Receptor Agonist (oral).

Medically reviewed by Dr. Sarah Chen, PharmD • Last updated April 2026

Check Eligibility
Wegovy Pill semaglutide medication product image

FDA Status

Approved

Manufacturer

Novo Nordisk

Generic Name

semaglutide

Typical Cost

$149-299/mo

Delivery Method

Oral tablet

What is Wegovy Pill?

Wegovy Pill is an oral GLP-1 receptor agonist medication manufactured by Novo Nordisk, FDA-approved in 2025 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Its active ingredient, semaglutide, works by mimicking the GLP-1 hormone to reduce appetite, increase satiety, and slow gastric emptying — delivered via a daily tablet using an absorption-enhancing formulation. In the OASIS 4 clinical trial, patients taking the 25 mg oral dose lost an average of 13.6% of body weight over 64 weeks; treatment completers achieved 16.6% mean weight loss. Wegovy Pill is taken once daily on an empty stomach with no more than 4 oz of plain water, followed by a 30-minute fast before eating. As of April 2026, Wegovy Pill costs approximately $149–299 per month without insurance through NovoCare savings programs, and insurance coverage can significantly reduce out-of-pocket costs. At $149/month for the starter dose, it is the most affordable brand-name GLP-1 weight-loss option currently available.

Overview

Launched January 2026, the oral Wegovy tablet is the first oral GLP-1 approved specifically for weight management. Available at $149/month for the starter dose through some programs.

Pricing

Typical retail pricing for Wegovy Pill is approximately $149-299/mo without insurance. Compounded alternatives may be available at lower cost through telehealth providers.

How It Works

Wegovy Pill (semaglutide) works as a GLP-1 Receptor Agonist (oral). It mimics natural hormones that regulate appetite, blood sugar, and satiety signals.

Common Side Effects

  • Nausea (typically worst during dose escalation)
  • Diarrhea and constipation
  • Headache and fatigue
  • Reduced appetite (the intended therapeutic effect)

How It Compares

The Wegovy Pill (oral semaglutide) competes directly with Foundayo (orforglipron) — Eli Lilly’s oral GLP-1 approved in April 2026. Foundayo has no meal-timing restrictions; oral Wegovy requires a 30-minute fasting window. Pricing is currently similar. See Foundayo vs Wegovy Pill for the head-to-head.

Versus the injectable Wegovy pen, the pill offers needle-free convenience with comparable weight-loss data in clinical trials, though real-world outcomes data is still emerging. See Wegovy Pill vs Wegovy Injection for a direct comparison.

For the format question broadly, see oral vs injectable GLP-1 medications.

Frequently Asked Questions

How much does the Wegovy Pill cost per month?

The Wegovy Pill costs approximately $149–299 per month without insurance through NovoCare as of April 2026, depending on your dose level. The starter dose is priced at the lower end ($149/month), making it the most affordable brand-name GLP-1 weight-loss medication currently available — significantly cheaper than injectable Wegovy ($349/month through NovoCare) or Zepbound ($299–449/month through LillyDirect). With commercial insurance and the Novo Nordisk NovoCare savings card, eligible patients can pay as little as $0–25 per month in copays. Novo Nordisk priced the oral version aggressively to compete directly with compounded semaglutide telehealth providers and Eli Lilly’s Foundayo ($149/month). As of April 2026, the competitive oral GLP-1 landscape has dramatically reduced what patients need to pay for brand-name weight-loss therapy — the era of $1,000+/month being unavoidable is effectively over for many patients. Use our cost calculator to compare your specific access pathway.

How do I take the Wegovy Pill?

Take the Wegovy Pill first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications — this fasting window is critical for proper absorption. The oral semaglutide formulation uses a sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) absorption enhancer that temporarily changes stomach pH to allow the semaglutide peptide to be absorbed through the gastric mucosa. Food, other liquids, or medications taken at the same time disrupt this process and can reduce bioavailability by 50% or more, significantly undermining the medication’s effectiveness. Clinical trials enforced this protocol rigorously — real-world adherence to the fasting window is directly correlated with outcomes. Common pitfalls: taking the pill with morning coffee or juice, waiting only 15 minutes instead of 30, or swallowing it alongside vitamins or other medications. If the fasting requirement is a barrier for your lifestyle, Foundayo (orforglipron) — a competing oral GLP-1 — can be taken any time with or without food.

Is the Wegovy Pill as effective as the Wegovy injection?

Clinical trial data shows closely comparable weight-loss outcomes between the oral and injectable semaglutide formulations. In the OASIS 4 trial, the 25 mg oral dose achieved 13.6% mean weight loss over 64 weeks; treatment completers reached 16.6%. The injectable Wegovy achieved 14.9% in STEP-1 over 68 weeks. The ~1.3% difference is relatively small and may reflect differences in trial design, duration, and population rather than a true efficacy gap. At the 50 mg dose tested in OASIS 1, oral semaglutide showed 15.1% weight loss — essentially matching the injection. Real-world adherence data for the oral Wegovy Pill is still emerging given its early 2026 launch. Some patients find the daily pill easier to maintain than weekly injections; others prefer the once-weekly injection over a strict daily morning fasting routine. The most important factor is adherence — the formulation you consistently take correctly will outperform the one you skip. Discuss your lifestyle with your provider to determine which format fits better.

Wegovy Pill vs Foundayo — which oral GLP-1 is better?

Both are oral weight-loss pills launched in 2025–2026, but they differ meaningfully in convenience, mechanism, and clinical track record. The biggest practical difference is timing: Foundayo (orforglipron) can be taken any time of day with or without food — no fasting required; Wegovy Pill requires morning fasting and a 30-minute wait. For patients who struggle with strict morning routines, Foundayo is meaningfully more convenient. Mechanistically, Wegovy Pill uses semaglutide — a peptide-based GLP-1 agonist with years of clinical data, including cardiovascular outcomes from the SELECT trial; Foundayo uses orforglipron, a newer non-peptide small molecule with data from the ATTAIN-1 trial (12.4% weight loss) but a shorter clinical track record. In head-to-head-equivalent trial data, Wegovy Pill shows slightly higher weight loss (13.6% vs 12.4%), though these were separate trials and not a direct comparison. Both are priced at $149–299/month. For most patients, the convenience vs. efficacy trade-off makes the choice personal. See the Foundayo vs Wegovy Pill comparison.

Can I switch from Wegovy injection to the Wegovy Pill?

Yes — and Novo Nordisk designed the oral formulation to provide a transition option for patients on injectable Wegovy who want needle-free convenience. Since both formulations contain semaglutide, the switch is pharmacologically familiar, though the doses are not directly equivalent — oral semaglutide requires higher milligram doses to achieve the same blood levels as the injection due to lower oral bioavailability. Your provider will determine the appropriate starting oral dose based on your current injection dose, your response to therapy, and tolerance history. Most patients don’t start from the very lowest oral dose, but titration is still recommended. In the OASIS 4 trial, patients on the 25 mg oral dose achieved 13.6% weight loss, comparable to the injection’s 14.9% in STEP-1 — suggesting the switch can preserve most of your treatment gains. Common reasons patients switch: injection site fatigue, needle anxiety, lifestyle preference for a daily pill, and the substantially lower cost of the oral formulation through NovoCare ($149–299/month vs $349/month for the injection).

Is the Wegovy Pill covered by insurance?

Insurance coverage for the Wegovy Pill is expanding as of April 2026. Many commercial employer plans that already covered injectable Wegovy are actively adding the oral formulation to their anti-obesity medication benefits. Since the Wegovy Pill carries the same FDA indication (chronic weight management, semaglutide 2.4mg equivalent) as the injectable, it qualifies under the same anti-obesity coverage provisions — meaning it’s eligible under weight-management formularies rather than diabetes-only coverage. Prior authorization is typically required, and insurers generally verify BMI ≥30 (or ≥27 with comorbidities) and prior treatment history. Coverage terms vary significantly by plan — some may cover the injectable but not the oral, or vice versa, depending on formulary placement decisions. The good news: even without insurance, the NovoCare self-pay program prices the oral Wegovy at $149/month for the starter dose — one of the most accessible pricing points for any branded GLP-1. Check your plan’s formulary online or call member services with the NDC code for the specific dose you’ve been prescribed.

Keep Reading

Frequently Asked Questions

How much does the Wegovy Pill cost per month?
The Wegovy Pill costs approximately $149–299 per month without insurance through NovoCare as of April 2026, depending on your dose level. The starter dose is priced at the lower end ($149/month), making it the most affordable brand-name GLP-1 weight-loss medication currently available — significantly cheaper than injectable Wegovy ($349/month through NovoCare) or Zepbound ($299–449/month through LillyDirect). With commercial insurance and the Novo Nordisk NovoCare savings card, eligible patients can pay as little as $0–25 per month in copays. Novo Nordisk priced the oral version aggressively to compete directly with compounded semaglutide telehealth providers and Eli Lilly's Foundayo ($149/month). As of April 2026, the competitive oral GLP-1 landscape has dramatically reduced what patients need to pay for brand-name weight-loss therapy — the era of $1,000+/month being unavoidable is effectively over for many patients. Use our cost calculator to compare your specific access pathway.
How do I take the Wegovy Pill?
Take the Wegovy Pill first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications — this fasting window is critical for proper absorption. The oral semaglutide formulation uses a sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) absorption enhancer that temporarily changes stomach pH to allow the semaglutide peptide to be absorbed through the gastric mucosa. Food, other liquids, or medications taken at the same time disrupt this process and can reduce bioavailability by 50% or more, significantly undermining the medication's effectiveness. Clinical trials enforced this protocol rigorously — real-world adherence to the fasting window is directly correlated with outcomes. Common pitfalls: taking the pill with morning coffee or juice, waiting only 15 minutes instead of 30, or swallowing it alongside vitamins or other medications. If the fasting requirement is a barrier for your lifestyle, Foundayo (orforglipron) — a competing oral GLP-1 — can be taken any time with or without food.
Is the Wegovy Pill as effective as the Wegovy injection?
Clinical trial data shows closely comparable weight-loss outcomes between the oral and injectable semaglutide formulations. In the OASIS 4 trial, the 25 mg oral dose achieved 13.6% mean weight loss over 64 weeks; treatment completers reached 16.6%. The injectable Wegovy achieved 14.9% in STEP-1 over 68 weeks. The ~1.3% difference is relatively small and may reflect differences in trial design, duration, and population rather than a true efficacy gap. At the 50 mg dose tested in OASIS 1, oral semaglutide showed 15.1% weight loss — essentially matching the injection. Real-world adherence data for the oral Wegovy Pill is still emerging given its early 2026 launch. Some patients find the daily pill easier to maintain than weekly injections; others prefer the once-weekly injection over a strict daily morning fasting routine. The most important factor is adherence — the formulation you consistently take correctly will outperform the one you skip. Discuss your lifestyle with your provider to determine which format fits better.
Wegovy Pill vs Foundayo — which oral GLP-1 is better?
Both are oral weight-loss pills launched in 2025–2026, but they differ meaningfully in convenience, mechanism, and clinical track record. The biggest practical difference is timing: Foundayo (orforglipron) can be taken any time of day with or without food — no fasting required; Wegovy Pill requires morning fasting and a 30-minute wait. For patients who struggle with strict morning routines, Foundayo is meaningfully more convenient. Mechanistically, Wegovy Pill uses semaglutide — a peptide-based GLP-1 agonist with years of clinical data, including cardiovascular outcomes from the SELECT trial; Foundayo uses orforglipron, a newer non-peptide small molecule with data from the ATTAIN-1 trial (12.4% weight loss) but a shorter clinical track record. In head-to-head-equivalent trial data, Wegovy Pill shows slightly higher weight loss (13.6% vs 12.4%), though these were separate trials and not a direct comparison. Both are priced at $149–299/month. For most patients, the convenience vs. efficacy trade-off makes the choice personal. See the Foundayo vs Wegovy Pill comparison.
Can I switch from Wegovy injection to the Wegovy Pill?
Yes — and Novo Nordisk designed the oral formulation to provide a transition option for patients on injectable Wegovy who want needle-free convenience. Since both formulations contain semaglutide, the switch is pharmacologically familiar, though the doses are not directly equivalent — oral semaglutide requires higher milligram doses to achieve the same blood levels as the injection due to lower oral bioavailability. Your provider will determine the appropriate starting oral dose based on your current injection dose, your response to therapy, and tolerance history. Most patients don't start from the very lowest oral dose, but titration is still recommended. In the OASIS 4 trial, patients on the 25 mg oral dose achieved 13.6% weight loss, comparable to the injection's 14.9% in STEP-1 — suggesting the switch can preserve most of your treatment gains. Common reasons patients switch: injection site fatigue, needle anxiety, lifestyle preference for a daily pill, and the substantially lower cost of the oral formulation through NovoCare ($149–299/month vs $349/month for the injection).
Is the Wegovy Pill covered by insurance?
Insurance coverage for the Wegovy Pill is expanding as of April 2026. Many commercial employer plans that already covered injectable Wegovy are actively adding the oral formulation to their anti-obesity medication benefits. Since the Wegovy Pill carries the same FDA indication (chronic weight management, semaglutide 2.4mg equivalent) as the injectable, it qualifies under the same anti-obesity coverage provisions — meaning it's eligible under weight-management formularies rather than diabetes-only coverage. Prior authorization is typically required, and insurers generally verify BMI ≥30 (or ≥27 with comorbidities) and prior treatment history. Coverage terms vary significantly by plan — some may cover the injectable but not the oral, or vice versa, depending on formulary placement decisions. The good news: even without insurance, the NovoCare self-pay program prices the oral Wegovy at $149/month for the starter dose — one of the most accessible pricing points for any branded GLP-1. Check your plan's formulary online or call member services with the NDC code for the specific dose you've been prescribed. ---
Affiliate Disclosure: GLP-1 Price Guide may receive a commission if you choose to utilize the services or tools linked on this page. Our research team maintains strict editorial independence to ensure objective pricing data.